Home › Glioblastoma › North Carolina
Glioblastoma clinical trials in North Carolina
26 studies for Glioblastoma are looking for participants at sites in North Carolina.
Cities in North Carolina
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
- University of North Carolina, Chapel Hill
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05902169Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care
- East Carolina University, Greenville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT07195591Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05432804A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- Comprehensive Cancer Center of Wake Forest*, Winston-Salem
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT03970447A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Levine Children's Hospital- Pediatric Neuro-Oncology, Charlotte
RecruitingPhase 1/2
Up to age 25 · All sexes · Updated Sep 25, 2026 · NCT04094610Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas
- Wake Forest University, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT05139056Targeted Pediatric High-Grade Glioma Therapy
- Duke University Health System, Durham
RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
- Carolinas Medical Center/Levine Cancer Institute, Charlotte
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594Study of Olutasidenib and Temozolomide in HGG
- Duke University Health System, Durham
RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
- Duke Cancer Institute, Durham
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT04903795Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
- Duke University Medical Center, Durham
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT06319027A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment
- Duke University, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT05708352A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
- Duke University, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 31, 2026 · NCT06069726Lerapolturev (PVSRIPO) in GBM
- Duke University Medical Center, Durham
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 20, 2026 · NCT06177964DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill
- Wake Forest University Health Sciences, Winston-Salem
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 1, 2026 · NCT06805305Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
- Duke University Health System, Durham
RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT04547777Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
- Duke University Health System, Durham
RecruitingPhase 2
12 Months – 39 Years · All sexes · Updated May 29, 2026 · NCT05843253Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc
- Lineberger Comprehensive Cancer Center, Chapel Hill
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 22, 2026 · NCT05366179Key Longitudinal Associations With Risk and Glioblastoma Outcomes
- Duke University, Durham
RecruitingObservational study
Ages 18 and older · All sexes · Updated Jan 20, 2026 · NCT06625684SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Chapel Hill
- Massive Bio SYNERGY-AI site, Winston-Salem
RecruitingObservational study
All ages · All sexes · Updated Oct 28, 2025 · NCT03452774D2C7-IT + 2141-V11 Combination Post-resection in rGBM
- Duke University Medical Center, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 23, 2025 · NCT06455605D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients
- Duke University Medical Center, Durham
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 6, 2025 · NCT05734560APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- University of North Carolina, Chapel Hill
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jun 27, 2025 · NCT03175224Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
- Duke University, Durham
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 25, 2025 · NCT05879367From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.